Rezolute is a late stage clinical-stage biopharmaceutical company developing novel therapies for diseases caused by chronic glucose imbalance.
Rezolute is preparing to initiate a global Phase 3 trial for their lead clinical asset, RZ358, which is a potential treatment for Congenital Hyperinsulinism (CHI), an ultra-rare pediatric genetic disorder characterized by excessive production of insulin by the pancreas.
The company’s second clinical-stage asset, currently in Phase 2, RZ402, is a selective and potent plasma kallikrein inhibitor (PKI) being developed as a potential oral therapy for the chronic treatment of diabetic macular edema (DME)